Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1983 May;80(9):2713–2717. doi: 10.1073/pnas.80.9.2713

In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor

Matthew K Waldor *,†, Subramaniam Sriram *,†, Hugh O McDevitt ‡, Lawrence Steinman *,†
PMCID: PMC393898  PMID: 6405386

Abstract

A monoclonal antibody to I-A gene products of the immune response gene complex attenuates both humoral and cellular responses to acetylcholine receptor and appears to suppress clinical manifestations of experimental autoimmune myasthenia gravis. This demonstrates that use of antibodies against immune response gene products that are associated with susceptibility to disease may be feasible for therapy in autoimmune conditions such as myasthenia gravis.

Keywords: autoimmune disease, I region, monoclonal antibodies, myasthenia gravis

Full text

PDF
2713

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berman P. W., Patrick J. Experimental myasthenia gravis. A murine system. J Exp Med. 1980 Jan 1;151(1):204–223. doi: 10.1084/jem.151.1.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berman P. W., Patrick J. Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis. J Exp Med. 1980 Sep 1;152(3):507–520. doi: 10.1084/jem.152.3.507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berzofsky J. A., Richman L. K. Genetic control of the immune response to myoglobins. IV. Inhibition of determinant-specific Ir gene-controlled antigen presentation and induction of suppression by pretreatment of presenting cells with anti-Ia antibodies. J Immunol. 1981 May;126(5):1898–1904. [PubMed] [Google Scholar]
  4. Christadoss P., Lennon V. A., David C. Genetic control of experimental autoimmune myasthenia gravis in mice. I. Lymphocyte proliferative response to acetylcholine receptors is under H-2-linked Ir gene control. J Immunol. 1979 Dec;123(6):2540–2543. [PubMed] [Google Scholar]
  5. Dau P. C., Lindstrom J. M., Cassel C. K., Denys E. H., Shev E. E., Spitler L. E. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med. 1977 Nov 24;297(21):1134–1140. doi: 10.1056/NEJM197711242972102. [DOI] [PubMed] [Google Scholar]
  6. Davies D. A., Staines N. A. A cardinal role for I-region antigens (Ia) in immunological enhancement, and the clinical implications. Transplant Rev. 1976;30:18–39. doi: 10.1111/j.1600-065x.1976.tb00213.x. [DOI] [PubMed] [Google Scholar]
  7. De Baets M. H., Einarson B., Lindstrom J. M., Weigle W. O. Lymphocyte activation in experimental autoimmune myasthenia gravis. J Immunol. 1982 May;128(5):2228–2235. [PubMed] [Google Scholar]
  8. Elliott J., Blanchard S. G., Wu W., Miller J., Strader C. D., Hartig P., Moore H. P., Racs J., Raftery M. A. Purification of Torpedo californica post-synaptic membranes and fractionation of their constituent proteins. Biochem J. 1980 Mar 1;185(3):667–677. doi: 10.1042/bj1850667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fuchs S., Nevo D., Tarrab-Hazdai R., Yaar I. Strain differences in the autoimmune response of mice to acetylcholine receptors. Nature. 1976 Sep 23;263(5575):329–330. doi: 10.1038/263329a0. [DOI] [PubMed] [Google Scholar]
  10. Gabourel J. D., Moore M. A., Bagby G. C., Jr, Davies G. H. Effect of sodium salicylate on human and mouse granulopoiesis in vitro. Arthritis Rheum. 1977 Jan-Feb;20(1):59–64. doi: 10.1002/art.1780200112. [DOI] [PubMed] [Google Scholar]
  11. Greene M. I., Dorf M. E., Pierres M., Benacerraf B. Reduction of syngeneic tumor growth by an anti-I-J-alloantiserum. Proc Natl Acad Sci U S A. 1977 Nov;74(11):5118–5121. doi: 10.1073/pnas.74.11.5118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Heinemann S., Bevan S., Kullberg R., Lindstrom J., Rice J. Modulation of acetylcholine receptor by antibody against the receptor. Proc Natl Acad Sci U S A. 1977 Jul;74(7):3090–3094. doi: 10.1073/pnas.74.7.3090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kao I., Drachman D. B. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science. 1977 Apr 29;196(4289):527–529. doi: 10.1126/science.850793. [DOI] [PubMed] [Google Scholar]
  14. Meruelo D., Flieger N., Smith D., McDevitt H. O. In vivo or in vitro treatments with anti-I-J alloantisera abolish immunity to AKR leukemia. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2178–2182. doi: 10.1073/pnas.77.4.2178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Norcross N. L., Griffith I. J., Lettieri J. A. Measurement of acetylcholine receptor and anti-receptor antibodies by ELISA. Muscle Nerve. 1980 Jul-Aug;3(4):345–349. doi: 10.1002/mus.880030412. [DOI] [PubMed] [Google Scholar]
  16. Oi V. T., Jones P. P., Goding J. W., Herzenberg L. A., Herzenberg L. A. Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. Curr Top Microbiol Immunol. 1978;81:115–120. doi: 10.1007/978-3-642-67448-8_18. [DOI] [PubMed] [Google Scholar]
  17. Perry L. L., Greene M. I. Conversion of immunity to suppression by in vivo administration of I-A subregion-specific antibodies. J Exp Med. 1982 Aug 1;156(2):480–491. doi: 10.1084/jem.156.2.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pestronk A., Drachman D. B., Adams R. N. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle Nerve. 1982 Jan;5(1):79–84. doi: 10.1002/mus.880050115. [DOI] [PubMed] [Google Scholar]
  19. Rosenbaum J. T., Adelman N. E., McDevitt H. O. In vivo effects of antibodies to immune response gene products. I. Haplotype-specific suppression of humoral immune responses with a monoclonal anti-I-A. J Exp Med. 1981 Nov 1;154(5):1694–1702. doi: 10.1084/jem.154.5.1694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Schmidt J., Raftery M. A. A simple assay for the study of solubilized acetylcholine receptors. Anal Biochem. 1973 Apr;52(2):349–354. doi: 10.1016/0003-2697(73)90036-5. [DOI] [PubMed] [Google Scholar]
  21. Schwartz M., Novick D., Givol D., Fuchs S. Induction of anti-idiotypic antibodies by immunisation with syngeneic spleen cells educated with acetylcholine receptor. Nature. 1978 Jun 15;273(5663):543–545. doi: 10.1038/273543a0. [DOI] [PubMed] [Google Scholar]
  22. Sprent J. Effects of blocking helper T cell induction in vivo with anti-Ia antibodies. Possible role of I-A/E hybrid molecules as restriction elements. J Exp Med. 1980 Oct 1;152(4):996–1010. doi: 10.1084/jem.152.4.996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Steinman L., Rosenbaum J. T., Sriram S., McDevitt H. O. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci U S A. 1981 Nov;78(11):7111–7114. doi: 10.1073/pnas.78.11.7111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Säfwenberg J., Hammarström L., Lindblom J. B., Matell G., Möller E., Osterman P. O., Smith C. I. HLA-A, -B, -C and -D antigens in male patients with myasthenia gravis. Tissue Antigens. 1978 Aug;12(2):136–142. doi: 10.1111/j.1399-0039.1978.tb01309.x. [DOI] [PubMed] [Google Scholar]
  25. Tzartos S. J., Seybold M. E., Lindstrom J. M. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci U S A. 1982 Jan;79(1):188–192. doi: 10.1073/pnas.79.1.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Vincent A. Idiotype restriction in myasthenia gravis antibodies. Nature. 1981 Mar 26;290(5804):293–294. doi: 10.1038/290293a0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES